Frost & Sullivan Publishes Update Coverage Report on RedHill Biopharma Ltd. Net revenues for 2017 met expectations at $4M; likely capital raising in mid2018 when Phase III results for Crohn's disease are announced; Price target raised to NIS 2.59

Equity Research is published in the framework of the Tel Aviv Stock Exchange TASE Analysis Program TEL AVIV Israel March 14 2018 PRNewswire TASE analysis project was launched in 2016 in o...